Name: IGC Pharma, Inc. (IGC) Financial Statements
Creator: FinSpry

IGC Pharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

IGC Pharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Period Ending	Dec 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2019
Revenue & Gross Profit
Revenue	1.27	1.35	0.91	0.40	0.90	5.12
Cost of Revenue	0.65	0.61	0.47	0.20	0.31	4.98
Gross Profit	0.62	0.73	0.44	0.19	0.11	0.13
Operating Expenses
Research & Development	3.66	3.77	3.46	2.30	0.90	1.26
Selling, General & Administrative	4.41	6.76	8.55	13.29	7.91	3.52
Operating Expenses	8.07	10.53	12.01	15.62	8.81	4.78
Operating Income	-7.45	-9.80	-11.57	-15.43	-8.72	-4.64
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.33	0.10	0.10	0.41	0.09	0.55
Income
Income Before Tax	-7.12	-13.00	-11.51	-15.02	-8.81	-4.10
Income Tax Expense	0.00	0.00	0.00	-0.39	-0.08	0.00
Net Income	-7.12	-13.00	-11.51	-15.02	-8.81	-4.10
Net Income - Continuous Operations	-7.12	-13.00	-11.51	-15.02	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-6.83	-9.16	-10.91	-14.75	-8.25	-4.58
EBIT	-7.45	-9.80	-11.57	-15.40	-8.72	-4.64
Depreciation & Amortization	0.62	0.64	0.66	0.63	0.46	0.00
Earnings Per Share
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Shares Outstanding	76.52	58.84	52.58	49.99	41.96	35.39
Diluted Shares Outstanding	76.52	58.84	52.58	49.99	41.96	35.39